Psychosis associated with usage of herbal slimming products adulterated with sibutramine: A case series

Clinical Toxicology

Volumn 48, Issue 8, 2010, Pages 832-838

  Chen, Sammy P L ^a   Tang, Magdalene H Y ^a   Ng, Sau Wah ^a   Poon, Wing Tat ^a   Chan, Albert Y W ^a   Mak, Tony W L ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Chinese medicine; Psychosis; Sibutramine

Indexed keywords

FENFLURAMINE; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; MAZINDOL; N BISNORSIBUTRAMINE; N NORSIBUTRAMINE; PHENOLPHTHALEIN; SIBUTRAMINE; SPIRONOLACTONE; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; AUDITORY HALLUCINATION; CLINICAL ARTICLE; CLINICAL FEATURE; DELUSION; FEMALE; HONG KONG; HUMAN; INTERNET; MALE; OUTCOME ASSESSMENT; PSYCHOSIS; RETROSPECTIVE STUDY; SUICIDAL IDEATION; SYMPTOM; VISUAL HALLUCINATION; DRUG CONTAMINATION; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; TOXICITY;

ANIMALIA;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; CYCLOBUTANES; DRUG CONTAMINATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; RETROSPECTIVE STUDIES;

EID: 77958596609     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2010.517208     Document Type: Article

References (24)

1. Obesity and overweight (WHO factsheet). World Health Organization, September 2006. http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed 16 January 2010.
2. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999; 33(9):968-978
3. Registered Pharmaceuticals in Hong Kong. Department of Health. The Government of HKSAR. http://www.psdh.gov.hk/eps/productSearch SimpleAction.do. Accessed 20 January 2010.
4. Muller D, Weinmann W, Hermanns-Clausen M. Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int 2009; 106(13):218-222.
5. Yuen YP, Lai CK, Poon WT, Ng SW, Chan AY, Mak TW. Adulteration of over-the-counter slimming products with pharmaceutical analogue-an emerging threat. Hong Kong Med J 2007; 13(3):216-220.
6. Minns AB, Ebrahimi S, Te L, Ly B, Clark RF, Cantrell FL. A retrospec-tive review of California poison control system data of sibutramine exposures. Clin Toxicol (Phila) 2009; 47(8):814-817.
7. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000; 157(12):2057-2058.
8. Cordeiro Q, Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5(3):283-284.
9. Litvan L, Alcoverro-Fortuny O. Sibutramine and psychosis. J Clin Psychopharmacol 2007; 27(6):726-727.
10. Fernandez P, Peiro AM. A sibutramine-induced delusional disorder relapse. J Neuropsychiatry Clin Neurosci 2007; 19(1):88-89.
11. Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutra-mine: a case report and pathophysiologic correlation. J Psychosom Res2008; 64(1):107-109.
12. Dogangun B, Bolat N, Rustamov I, Kayaalp L. Sibutramine-induced psychotic episode in an adolescent. J Psychosom Res 2008; 65(5):505-506.
13. Mei. Sibutramine and manic psychosis, 2004. http://www.lareb.nl/ documents/kwb-2002-1-sibut.pdf. Accessed 20 October 2009.
14. Gazdag G, Szabo Z. Sibutramine-associated psychosis (case report). Neuropsychopharmacol Hung 2008; 10(2):107-110.
15. Zou P, Oh SS, Kiang KH, Low MY, Bloodworth BC. Detection of sibutramine, its two metabolites and one analogue in a herbal product for weight loss by liquid chromatography triple quadrupole mass spec-trometry and time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2007; 21(4):614-618.
16. The use of the WHO-UMC system for standardised case causality assessment. http://www.who-umc.org/graphics/4409.pdf. Accessed 10 July 2010.
17. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA. Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006; 145(2):81-90.
18. Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Dis-continuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10(5):564-575
19. European Medicines Agency recommends suspension of marketing authorisations for sibutramine: European Medicines Agency, 2010. http://www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf. Accessed 20 March 2010.
20. Sayburn A. Withdrawal of sibutramine leaves European doctors with just one obesity drug. BMJ 2010; 340:c477.
21. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000; 1(2):127-139.
22. Foltin RW, Fischman MW. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 1991; 28(1):3-48.
23. Myers JE, Mieczkowski T, Perel J, Abbondanza D, Cooper TB, Mann JJ. Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders. Correlation with increased seroton-ergic responsivity. Biol Psychiatry 1994; 35(2):112-120.
24. Preval H, Pakyurek AM. Psychotic episode associated with dexfenflu-ramine. Am J Psychiatry 1997; 154(11):1624-1625.